Results 241 to 250 of about 136,697 (349)
Varenicline for cannabis use disorder: A randomized controlled trial
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark +8 more
wiley +1 more source
Factors Associated With Adult Incarceration Among People With Opioid Use Disorder in New South Wales, Australia. [PDF]
Macdonald C +8 more
europepmc +1 more source
Mortality Among Veterans With Opioid Use Disorder After Medical Hospitalization
Michael Incze +6 more
openalex +2 more sources
Trends in fentanyl‐containing drug samples seized by law enforcement agencies across Canada
Abstract Background and aims Canada's drug toxicity crisis has been largely attributed to a volatile fentanyl‐dominated unregulated drug supply with increasing reports of fentanyl detected in combination with benzodiazepines, stimulants and xylazine.
Shaleesa Ledlie +6 more
wiley +1 more source
A lifeline on wheels: perspectives of stakeholders on the implementation and impact of a mobile medications for opioid use disorder unit. [PDF]
Kang A, Bailey A, Hurley L, Martin R.
europepmc +1 more source
Neuromodulation for opioid use disorder in Canada : risks, benefits, values, and justice [PDF]
Boyle, Quinn
openalex
Abstract Background and aims The state of Kentucky has been heavily impacted by the ongoing opioid crisis in the United States, with high overdose mortality, high prevalence of opioid use disorder (OUD), elevated maternal mortality and incidence of Neonatal Abstinence Syndrome.
Hilary L. Surratt +9 more
wiley +1 more source
Older Age Is Associated With Long-Term Retention in Buprenorphine Treatment for Opioid Use Disorder. [PDF]
Groeger JL +11 more
europepmc +1 more source
Abstract Revived interest in psychedelic‐assisted therapies has also renewed focus on ibogaine, a psychoactive alkaloid, for its notable anti‐addictive potential. Evidence from observational, open‐label, and limited randomized placebo‐controlled trials indicates that ibogaine and its metabolite noribogaine reduce craving and withdrawal symptoms in ...
Tibor Markus Brunt
wiley +1 more source

